Edwards Lifesciences Corporation (BVMF:E1WL34)

Market Cap	238.40B -0.9%
Revenue (ttm)	31.36B +10.6%
Net Income	7.29B -67.1%
EPS	12.42 -66.2%
Shares Out	n/a
PE Ratio	32.70
Forward PE	27.94
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3
Average Volume	176
Open	101.64
Previous Close	103.04
Day's Range	101.64 - 101.64
52-Week Range	98.15 - 120.94
Beta	0.94
RSI	29.15
Earnings Date	Feb 10, 2026

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. The company offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband brands. It also provides surgical structural heart solution...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1958
• Employees: 15,800
• Stock Exchange: Brazil Stock Exchange
• Ticker Symbol: E1WL34

Financial Performance

In 2024, Edwards Lifesciences's revenue was $5.44 billion, an increase of 8.57% compared to the previous year's $5.01 billion. Earnings were $4.17 billion, an increase of 197.68%.

Financial numbers in USD